David S. Tierney, MD, currently serves as CEO of Icon Bioscience Inc., a privately held ophthalmic drug delivery company. Previously, Dr. Tierney served as President and Chief Operating Officer and Director of Oceana Therapeutics, Inc., which was acquired by Salix Pharmaceuticals, Inc. in December 2011. Previously, Dr. Tierney was the President, Chief Executive Officer and a director of Valera Pharmaceuticals, Inc., until it was acquired by Indevus Pharmaceuticals, Inc., in April 2007. From January 2000 to August 2000, Dr. Tierney served as President of Biovail Technologies, a division of Biovail Corporation, a Canadian drug delivery company, where he had responsibility for all of Biovail's research and development and regulatory and clinical activities. From March 1997 to January 2000, Dr. Tierney was Senior Vice President of Drug Development at Roberts Pharmaceutical Corporation, with responsibility for all research and development activities, and overall responsibility for drug development, medical affairs, worldwide regulatory affairs and chemical process development, as well as being part of the executive management team. From December 1989 to March 1997, Dr. Tierney was at Élan Corporation in a variety of management positions. Dr. Tierney received his medical degree from the Royal College of Surgeons in Dublin, Ireland, and subsequently trained in internal medicine. Dr. Tierney also serves on the board of directors of Bioject Medical Technologies, Inc.
What is David S. Tierney's net worth?
The estimated net worth of David S. Tierney is at least $8.76 million as of August 27th, 2025. Dr. Tierney owns 379,620 shares of Catalyst Pharmaceuticals stock worth more than $8,761,630 as of December 4th. This net worth evaluation does not reflect any other investments that Dr. Tierney may own. Learn More about David S. Tierney's net worth.
How do I contact David S. Tierney?
Has David S. Tierney been buying or selling shares of Catalyst Pharmaceuticals?
David S. Tierney has not been actively trading shares of Catalyst Pharmaceuticals during the past quarter. Most recently, David S. Tierney sold 26,000 shares of the business's stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $20.20, for a transaction totalling $525,200.00. Following the completion of the sale, the director now directly owns 379,620 shares of the company's stock, valued at $7,668,324. Learn More on David S. Tierney's trading history.
Who are Catalyst Pharmaceuticals' active insiders?
Catalyst Pharmaceuticals' insider roster includes Philip Coelho (Director), Richard Daly (President and CEO), Jeffrey Del Carmen (EVP, Chief Commercial Officer), Donald Denkhaus (Director), Brian Elsbernd (Chief Legal and Compliance Officer), Alicia Grande (Vice President, Chief Financial Officer and Treasurer), Alicia Grande (CFO), Molly Harper (Director), Gary Ingenito (Insider), Patrick McEnany (CEO), Steve Miller (COO), Steven Miller (COO & Chief Scientific Officer ), Preethi Sundaram (Chief Strategy Officer), and David Tierney (Director). Learn More on Catalyst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Catalyst Pharmaceuticals?
In the last year, insiders at the biopharmaceutical company sold shares 14 times. They sold a total of 660,756 shares worth more than $14,598,438.49. The most recent insider tranaction occured on November, 26th when insider Carmen Jeffrey Del sold 10,983 shares worth more than $256,233.39. Insiders at Catalyst Pharmaceuticals own 10.4% of the company.
Learn More about insider trades at Catalyst Pharmaceuticals. Information on this page was last updated on 11/26/2025.
